Published in Dig Dis Sci on April 01, 2001
Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res (2010) 1.66
Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut (2006) 1.42
Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol (2012) 1.09
TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut (2006) 1.03
Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. Dig Dis Sci (2004) 1.01
Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis. Br J Cancer (2014) 0.92
Review: Experimental models for Barrett's esophagus and esophageal adenocarcinoma. Am J Physiol Gastrointest Liver Physiol (2012) 0.85
Abnormal expression of biomarkers in incompletely ablated Barrett's esophagus. Ann Surg (2006) 0.82
Nonsteroidal anti-inflammatory drugs and the risk of Barrett's esophagus. Clin Gastroenterol Hepatol (2014) 0.77
Barrett's oesophagus and adenocarcinoma. World J Surg Oncol (2004) 0.76
Endoscopic assessment and management of early esophageal adenocarcinoma. World J Gastrointest Oncol (2014) 0.76
Global tumor RNA expression in early establishment of experimental tumor growth and related angiogenesis following COX-inhibition evaluated by microarray analysis. Cancer Inform (2007) 0.75
Incorporation of Nissen fundoplication in a rat model of duodenoesophageal reflux. Surg Endosc (2006) 0.75
Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA (1991) 11.53
Aspirin and the risk of colorectal cancer in women. N Engl J Med (1995) 9.59
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol (1983) 8.24
Aspirin use and reduced risk of fatal colon cancer. N Engl J Med (1991) 7.85
Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell (1996) 7.46
Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell (1995) 6.69
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med (1993) 6.13
Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med (1994) 5.42
Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology (1994) 4.27
Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology (1989) 4.23
Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology (1993) 4.23
Aspirin use and risk of fatal cancer. Cancer Res (1993) 4.14
Altered eicosanoid levels in human colon cancer. J Lab Clin Med (1993) 3.32
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res (1998) 3.11
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99
A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst (1991) 2.96
Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg (1983) 2.91
Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res (1995) 2.74
Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem (1993) 2.61
Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res (1999) 2.51
Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology (1991) 2.43
Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology (1995) 2.23
Towards a better aspirin. Nature (1994) 2.20
Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology (1987) 2.15
Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. Hum Pathol (1992) 2.11
Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol (1988) 2.03
Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med (1991) 2.01
Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res (1997) 2.00
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res (1998) 1.94
Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest (1994) 1.89
Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci U S A (1996) 1.88
Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology (1996) 1.81
Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res (1996) 1.77
Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med (1998) 1.71
Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology (1996) 1.65
Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res (1996) 1.58
Aspirin and reduced risk of esophageal carcinoma. Cancer (1995) 1.56
Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst (1993) 1.26
Aspirin use, cancer, and polyps of the large bowel. Cancer (1993) 1.17
The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis (1998) 1.10
Regression of rectal adenomas after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Br Med J (Clin Res Ed) (1988) 1.05
Antitumoral activity of indomethacin on experimental esophageal tumors. J Natl Cancer Inst (1984) 0.88
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms. J Clin Microbiol (2001) 6.26
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer (2001) 4.62
Prostaglandins and cancer. Gut (2005) 3.44
Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology (2000) 3.32
Three-dimensional reconstruction of the antennal lobe in Drosophila melanogaster. J Comp Neurol (1999) 2.98
The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene (2009) 2.72
Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology (1998) 2.69
Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest (1994) 2.55
Eicosanoids and the gastrointestinal tract. Gastroenterology (1995) 2.04
Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology (1996) 1.81
Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology (2000) 1.75
Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology (1995) 1.74
Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology (1996) 1.65
Intravenous diuretic day-care treatment for patients with heart failure. Clin Med (2012) 1.38
15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res (2001) 1.37
Unemployment rates, single parent density, and indices of child poverty: their relationship to different categories of child abuse and neglect. Child Abuse Negl (1998) 1.30
Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest (1997) 1.25
K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res (2001) 1.22
Treatment of Ménétrier's disease with a monoclonal antibody against the epidermal growth factor receptor. N Engl J Med (2000) 1.20
Effect of phenobarbital administration to rats on the level of the in vitro synthesis of cytochrome P-450 directed by total rat liver RNA. Biochem Biophys Res Commun (1979) 1.04
Diversification of cyclooxygenase-2-derived prostaglandins in ovulation and implantation. Biol Reprod (2001) 1.00
Monocyte macrophage differentiation in vitro: Fibronectin-dependent upregulation of certain macrophage-specific activities. Glycoconj J (2007) 0.94
The classification of cyclooxygenase inhibitors. J Rheumatol (1998) 0.91
Effects of mesenteric ischemia and reperfusion on small bowel electrical activity. J Surg Res (1998) 0.90
Multiple gastric carcinoids in a patient with a history of primary hyperparathyroidism. Am J Gastroenterol (1985) 0.87
Large hypopharyngeal polyp producing intermittent dysphagia and acute airway obstruction. Am J Gastroenterol (1986) 0.86
Cyclooxygenase-2 alters transforming growth factor-beta 1 response during intestinal tumorigenesis. Surgery (1999) 0.85
Solitary rectal ulcer as a cause of massive lower gastrointestinal bleeding. Gastrointest Endosc (1985) 0.84
Pancreatic somatostatinoma: histologic, clinical, and angiographic features. AJR Am J Roentgenol (1979) 0.84
Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. Am J Gastroenterol (1999) 0.84
[Quantitative histological observations in gliomas (author's transl)]. Zentralbl Allg Pathol (1980) 0.83
Kupffer cell-derived cyclooxygenase-2 regulates hepatocyte Bcl-2 expression in choledocho-venous fistula rats. Am J Physiol Gastrointest Liver Physiol (2001) 0.83
Methylene blue staining and endoscopic ultrasound evaluation of Barrett's esophagus with low-grade dysplasia. Dig Dis Sci (2000) 0.83
Cyclooxygenase-2 downregulates inducible nitric oxide synthase in rat intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2001) 0.81
Provider attitudes and use of alternative medicine in a midwestern medical practice in 2001. WMJ (2001) 0.81
Mass screening of school children for heart disease. Public Health Rep (1969) 0.81
Traumatic hepatic duct injury: new approach to surgical management. Am J Surg (1980) 0.80
Intramucosal gastric carcinoma in a patient with familial polyposis coli. Am J Gastroenterol (1986) 0.80
The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. Cancer Chemother Pharmacol (1988) 0.80
Histopathologic changes during mesenteric ischaemia and reperfusion. West Afr J Med (2003) 0.80
Comparison of histochemical and biochemical assays for estrogen receptor in human breast cancer cell lines. Cancer Res (1984) 0.78
Systemic mastocytosis and mastocytosis-like syndrome: radiologic features of gastrointestinal manifestations. South Med J (1988) 0.78
Dysplastic gastroesophageal junction nodules--a precursor to junctional adenocarcinoma. Am J Gastroenterol (1999) 0.78
Superconducting quantum interference device magnetometer for diagnosis of ischemia caused by mesenteric venous thrombosis. World J Surg (1997) 0.77
Effect of allyl alcohol-induced sublethal hepatic damage upon doxorubicin metabolism and toxicity in the rabbit. Cancer Res (1987) 0.76
A model of cytochrome P-450-centered hepatic dysfunction in drug metabolism induced by cobalt-protoporphyrin administration. Biochem Pharmacol (1989) 0.76
Lipid metabolism and APC: implications for colorectal cancer prevention. Lancet (1997) 0.76
Adenocarcinoma of the esophagus associated with neurofibromatosis. J Tenn Med Assoc (1985) 0.75
Drug safety: can simple interventions be effective in a complex world? Pharmacoepidemiol Drug Saf (2001) 0.75
Prostaglandin E synthase: another enzyme in the cyclooxygenase pathway driving epithelial cancer? Clin Cancer Res (2001) 0.75
Biomechanical and clinical considerations in correcting skeletal class II malocclusion with Forsus™. J Contemp Dent Pract (2012) 0.75
[Pollution outside places of employment: introduction]. Acta Tuberc Pneumol Belg (1970) 0.75
[Polyovular follicles]. Gynecol Obstet Fertil (2010) 0.75
Cardiac output measured by earpiece densitometry vs. thermodilution. Crit Care Med (1984) 0.75
Electromagnetic fields and skin wound repair. J Microw Power (1975) 0.75
Pneumatic injury from a nailgun. Wis Med J (1985) 0.75
[Increase in longevity and its consequences]. Arch Belg Med Soc (1968) 0.75
Hand dysfunction due to carpal tunnel syndrome: a common sequela of dialysis. Proc Clin Dial Transplant Forum (1979) 0.75
Heart failure in the MI patient. Am J Nurs (1977) 0.75
[The cost of health]. Arch Belg Med Soc (1981) 0.75
[Secretary-General of the Ministry of Public Health and the Family, Dr. S. Halter]. Arch Belg Med Soc (1981) 0.75
[Description and commentary on American public health organization]. Arch Belg Med Soc (1966) 0.75
[International cooperation for medical assistance]. Landarzt (1964) 0.75
Medical-legal aspects of blood banking. J Ky Med Assoc (1966) 0.75
Dynamical energy analysis for built-up acoustic systems at high frequencies. J Acoust Soc Am (2011) 0.75
Changes in intestinal electrical activity during ischaemia correlate to pathology. West Afr J Med (2003) 0.75
Pharmacokinetics of inhalation anesthetics: a three-compartment linear model. Anesth Analg (1982) 0.75
A need to know. Nurs Times (1989) 0.75
Cclooxygenase-2 (COX-2) Protein Expression by Western Blotting. Methods Mol Med (2001) 0.75
Multidrug-resistant (MDR) Gram-negative bacteria information leaflets. J Hosp Infect (2016) 0.75
Adenoameloblastoma: a dilemma in diagnosis. J Contemp Dent Pract (2012) 0.75
[The concept of risk in epidemiology. Point of view of a public health officer (author's transl)]. Rev Epidemiol Sante Publique (1977) 0.75
De novo carcinoma of the rectum: a case report. Am J Gastroenterol (1985) 0.75
The need for international surveillance of biologicals: distribution, use, and efficacy. Bull World Health Organ (1977) 0.75
Noncirrhotic portal hypertension in congenital cytomegalovirus infection. Hepatology (1984) 0.75
Effect of sublethal liver injury on doxorubicin metabolism. Clin Cancer Res (1995) 0.75